Investigating the effectiveness of methylphenidate and combination of magnesium and zinc and calcium in treatment of patients with attention deficit hyperactivity disorder (ADHD) in Zahedan City

Investigating the effectiveness of methylphenidate and combination of magnesium and zinc and calcium in treatment of symptoms of attention deficit hyperactivity disorder (ADHD) among 6 to 12 children suffered from ADHD in Zahedan city

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015092624209N1

Enrollment

Registered

2016-04-24

Start date

2014-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit hyperactivity disorder (ADHD). Disturbance of activity and attention

Interventions

Intervention 1: In the intervention group: Methylphenidate tablets orally used with a starting dose of 0.3 mg/kg, twice a day up to a final dose of 1 mg/kg within two weeks and continue treatment unti

Treatment - Drugs

In the intervention group: Methylphenidate tablets orally used with a starting dose of 0.3 mg/kg, twice a day up to a final dose of 1 mg/kg within two weeks and continue treatment until 8 weeks after

In the control group: Methylphenidate tablets were used orally with a starting dose of 0.3 mg/kg twice a day up to a final dose of 1 mg/kg within two weeks and continue treatment until 8 weeks after i

Eligibility

Sex/Gender

All

Age

82 Years to 88 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Aged 6 to 12 years; diagnosis of attention deficit hyperactivity disorder (ADHD) based on DSM-IV-TR diagnostic criteria; the scale to measure attention deficit hyperactivity disorder (ADHD) in parent and teacher form, at least 20. Exclusion criteria: Any simultaneous major psychiatric disease, except confrontational behavior and learning disorder; IQ less than 70; the use of psychotropic drugs or narcotic materials in the past two weeks; any important neurological diseases; taking any drug affecting the nervous system, at least two weeks prior to the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Medication. Timepoint: Before intervention and 2, 4, 6 and 8 weeks after intervention. Method of measurement: Attention deficit hyperactivity disorder (ADHD) Rating Scale.	—

Secondary

Measure	Time frame
Side effects. Timepoint: Before intervention and 2, 4, 6 and 8 weeks after intervention. Method of measurement: Attention deficit hyperactivity disorder (ADHD) Rating Scale.;Disorder severity. Timepoint: Before intervention and 2, 4, 6 and 8 weeks after intervention. Method of measurement: Attention deficit hyperactivity disorder (ADHD) Rating Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Houshang Rafighdoust

Vice Chancellor for Research and Technology at Zahedan University of Medical Sciences and Health Ser

http://highmail.zaums.ac.ir+98 54 3329 5794

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026